TY - JOUR T1 - Dual CFTR modulator therapy efficacy in the real world: lessons for the future JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00464-2022 VL - 8 IS - 4 SP - 00464-2022 AU - Anna-Maria Dittrich AU - Sandra Y. Chuang Y1 - 2022/10/01 UR - http://openres.ersjournals.com/content/8/4/00464-2022.abstract N2 - Few diseases have undergone such transformative changes in the past four decades as cystic fibrosis. Cystic fibrosis has become the first example of the successful development of mutation-specific drugs. These drugs, known as cystic fibrosis transmembrane conductance regulator (CFTR) modulators, which improve the function of the CFTR channel, have been able to advance incrementally the overall positive development of therapeutic options in cystic fibrosis in only the last 10 years [1].Stringent analyses caution against drawing conclusions about the real-world efficacy of CFTR modulator therapy too early https://bit.ly/3dJt6no ER -